QC
TRDA icon

Quadrature Capital’s Entrada Therapeutics TRDA Stock Holding History

Quadrature Capital’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$221K Sell
17,538
-2,780
-14% -$31.9K ﹤0.01% 1084
2025
Q4 		$209K Buy
20,318
+2,424
+14% +$20.4K ﹤0.01% 961
2025
Q3 		$103K Buy
+17,894
New +$105K ﹤0.01% 868

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quadrature Capital's TRDA Position: Q1 2026 in Review

Quadrature Capital reduced its Entrada Therapeutics (TRDA) stake by 14% in Q1 2026, selling an estimated $31.9K and leaving 17,538 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #1084.

Quadrature Capital first reported a position in TRDA in Q3 2025 and has held it in 3 quarters since. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Quadrature Capital held 17,538 shares of Entrada Therapeutics worth $221K as of Q1 2026.
  • Quadrature Capital sold 2,780 Entrada Therapeutics shares in Q1 2026, an estimated $31.9K.
  • Entrada Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1084 holding.
  • Quadrature Capital first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.